1-Benzyl-3-toluenesulfonyloxypyrrolidine | 91832-69-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Benzyl-3-toluenesulfonyloxypyrrolidine
• 英文别名: (1-benzylpyrrolidin-3-yl) 2-methylbenzenesulfonate
• CAS: 91832-69-8
• 化学式: C₁₈H₂₁NO₃S
• 分子量: 331.436
• InChiKey: NTFXYWQMSDTJAG-UHFFFAOYSA-N

物化性质

• 沸点：
  464.5±45.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-Benzyl-3-toluenesulfonyloxypyrrolidine 在 sodium hydroxide 、 sodium methylate 作用下， 反应 5.0h， 生成 2-[(1-benzyl-3-pyrrolidinyl)oxy]-benzoic acid
  参考文献：
  名称：

  Benzo- and pyrido-1,4-oxazepin-5-ones and -thiones: synthesis and structure-activity relationships of a new series of H1-antihistamines

  摘要：

  A series of novel benzo- and pyrido-1,4-oxazepinones and -thiones which represents a new structural class of compounds possessing H1 antihistaminic activity was synthesized, and the SARs were evaluated. The antihistaminic activity was determined by blockade of histamine-induced lethality in guinea pigs. The sedative potential was determined by comparison of the EEG profiles of the compounds with those of known sedating and nonsedating antihistamines. Several of the compounds were shown to possess potent H1 antihistaminic activity and to be free of the cortical slowing with synchronized waves and spindling activity found in the EEG of sedative antihistamines. One compound, 2-[2-(dimethylamino)ethyl]-3,4-dihydro-4-methylpyrido[3,2-f]-1,4- oxazepine-5(2H)-thione (rocastine) is currently undergoing clinical evaluation as a nonsedating H1 antihistamine.

  DOI：

  10.1021/jm00129a026
• 作为产物：
  描述：

  N-苄基-3-吡咯烷醇 、 邻甲苯磺酰氯 在 sodium amide 作用下， 生成 1-Benzyl-3-toluenesulfonyloxypyrrolidine
  参考文献：
  名称：

  Benzo- and pyrido-1,4-oxazepin-5-ones and -thiones: synthesis and structure-activity relationships of a new series of H1-antihistamines

  摘要：

  A series of novel benzo- and pyrido-1,4-oxazepinones and -thiones which represents a new structural class of compounds possessing H1 antihistaminic activity was synthesized, and the SARs were evaluated. The antihistaminic activity was determined by blockade of histamine-induced lethality in guinea pigs. The sedative potential was determined by comparison of the EEG profiles of the compounds with those of known sedating and nonsedating antihistamines. Several of the compounds were shown to possess potent H1 antihistaminic activity and to be free of the cortical slowing with synchronized waves and spindling activity found in the EEG of sedative antihistamines. One compound, 2-[2-(dimethylamino)ethyl]-3,4-dihydro-4-methylpyrido[3,2-f]-1,4- oxazepine-5(2H)-thione (rocastine) is currently undergoing clinical evaluation as a nonsedating H1 antihistamine.

  DOI：

  10.1021/jm00129a026

文献信息

• Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20030064991A1

  公开（公告）日：2003-04-03

  Disclosed are novel compounds having the formula 1 or a physiologically acceptable salt, amide, ester or prodrug thereof. The compounds can be used to modulate (antagonize, agonize) chemokine receptor function. Also disclosed is a method for treating a patient having an inflammatory disease and/or viral infection comprising administering an effective amount of a compound of Formula I. In particular embodiments, the invention is a method for treating a patient infected with HIV.

  揭示了具有以下结构式的新化合物 1 或其生理上可接受的盐、酰胺、酯或前药。这些化合物可用于调节（拮抗、激动）趋化因子受体功能。还揭示了一种治疗患有炎症性疾病和/或病毒感染的患者的方法，包括给予结构式I的化合物的有效量。在特定实施例中，本发明是一种治疗感染HIV的患者的方法。
• SERINE HYDROLASE INHIBITORS
  申请人：Activx Biosciences, Inc.

  公开号：EP2066662A2

  公开（公告）日：2009-06-10
• US6951848B2
  申请人：——

  公开号：US6951848B2

  公开（公告）日：2005-10-04
• [EN] SERINE HYDROLASE INHIBITORS<br/>[FR] INHIBITEURS DE SERINE HYDROLASE
  申请人：ACTIVX BIOSCIENCES INC

  公开号：WO2008036379A2

  公开（公告）日：2008-03-27

  [EN] Provided herein are benzoxazinone compounds of formula (I) and compositions containing the compounds. The compounds and compositions are useful in the methods of inhibiting the action of serine hydrolase, including neutrophil elastase. In certain embodiments, the compounds and compositions are useful in the prevention, amelioration or treatment of serine hydrolase-mediated diseases.
  [FR] L'invention concerne des composés de benzoxaninone de formule (I) et des compositions renfermant ces composés. Ces composés et compositions sont utiles dans les méthodes d'inhibition de l'action de la sérine hydrolase, y compris de l'élastase neutrophile. Dans certains modes de réalisation, les composés et les compositions sont utiles dans la prévention, l'amélioration ou le traitement de maladies véhiculées par la sérine hydrolase.